AKTX - Akari Therapeutics, Plc Total Debt to Capital

The market trend for the separate_debt_total_eq metric on GURU.Markets is 0.04, illustrating the financial condition of Akari Therapeutics (AKTX). Akari Therapeutics (AKTX) develops biologics to treat severe autoimmune disorders, leveraging patent protection and the stability of physician prescribing habits. Its scientific potential is based on the development of nomacopan to combat rare inflammatory pathologies. The current stability of the business is entirely dependent on the outcomes of clinical trials for new therapy methods.

This indicator measures the proportion of borrowed funds within the capital structure, determining the degree of financial autonomy and the issuer's debt load risks. By analyzing the total debt-to-equity ratio on GURU.Markets, an investor can assess the ability of Akari Therapeutics (AKTX) to finance costly immunological developments and rare disease therapy partnerships without a critical dependence on external creditors.